|
|
Post by oncall on Jan 20, 2012 7:14:16 GMT -5
has layed off a bit of their CRU staff and are posting less studies. Is it true that their CRU is about 2 b taken over as result of lost of major funding as result of Lipitor patent expiring?  |
|
|
|
Post by carmel on Sept 6, 2012 3:05:56 GMT -5
has layed off a bit of their CRU staff and are posting less studies. Is it true that their CRU is about 2 b taken over as result of lost of major funding as result of Lipitor patent expiring? No, they won't be acquired by anyone. They acquired Wyeth back in 2009 which was quite a big merger. Lipitor sales had only begun to slump in 2009 when cash-strapped patients started looking for a cheaper alternative. It seems to me that has the same 7 studies. They have: $7k, $5500, $3900, $3300, $2400, $1320, and the $1025 study. lists the studies on a permanent graphic page: CRU. They should put it on a database type web page that can be updated. I remember calling them and not all those were listed. But they did tell me about the top two which should be all that matters anyway. No one wants to make less than $4k with these studies. You need to live near by New Haven also. Big down time between screening and study start date. There are also a large number of outpatient visits. 13 in total for the $7k study. |
|
|
|
Post by sam9009 on Nov 22, 2012 13:59:09 GMT -5
How long is that $7k study? I know it's 13 followup, but does that happen all in one month, two months etc...
Thanks.
|
|
|
|
Post by carmel on Feb 15, 2013 17:05:30 GMT -5
Actually, it does look like is struggling. It appears they are contracting Paraxel and Icon to do a lot of their studies. I'm not entirely sure which studies exactly, though. Here is an excerpt from a recent article by MedCity News: " also announced last year that it would be starting to use two contract research organizations -- outside groups brought in to conduct basic scientific studies -- as it ued a worldwide downsizing. But a spokeswoman said the increased use of these research firms, Boston-based PAREXEL International Corp. and Dublin-based ICON plc., was simply a streamlining of its use of outside firms and did not have any effect on local employment figures." Source: MedCity News |
|
